共 50 条
NT-proBNP is a weak indicator of cardiac function and haemodynamic response to exercise in chronic heart failure
被引:16
|作者:
Parovic, Milos
[1
,2
]
Okwose, Nduka C.
[1
,2
]
Bailey, Kristian
[3
]
Velicki, Lazar
[4
,5
]
Fras, Zlatko
[6
,7
]
Seferovic, Petar M.
[8
,9
,10
]
MacGowan, Guy A.
[1
,2
,3
]
Jakovljevic, Djordje G.
[1
,2
,3
,11
]
机构:
[1] Newcastle Univ, Cardiovasc Res Ctr, Inst Cellular Med, Newcastle Upon Tyne, Tyne & Wear, England
[2] Newcastle Univ, Fac Med Sci, Inst Genet Med, Newcastle Upon Tyne, Tyne & Wear, England
[3] Newcastle Upon Tyne Hosp NHS Fdn Trust, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England
[4] Univ Novi Sad, Fac Med, Novi Sad, Serbia
[5] Inst Cardiovasc Dis Vojvodina, Dept Cardiovasc Surg, Sremska Kamenica, Serbia
[6] Univ Med Ctr Ljubljana, Dept Vasc Dis, Div Internal Med, Ljubljana, Slovenia
[7] Univ Ljubljana, Fac Med, Dept Internal Med, Ljubljana, Slovenia
[8] Univ Belgrade, Med Sch, Cardiol Dept, Belgrade, Serbia
[9] Clin Ctr Serbia, Belgrade, Serbia
[10] Serbian Acad Arts & Sci, Belgrade, Serbia
[11] Newcastle Univ, RCUK Ctr Ageing & Vital, Newcastle Upon Tyne, Tyne & Wear, England
来源:
ESC HEART FAILURE
|
2019年
/
6卷
/
02期
基金:
欧盟地平线“2020”;
关键词:
Heart failure;
NT-proBNP;
Cardiac power;
Exercise;
POWER OUTPUT;
BIOREACTANCE;
CAPACITY;
D O I:
10.1002/ehf2.12424
中图分类号:
R5 [内科学];
学科分类号:
1002 ;
100201 ;
摘要:
Aims N-terminal prohormone of brain natriuretic peptide (NT-proBNP) plays an important role in diagnosis and management of heart failure. The aim of the present study was to assess haemodynamic response to exercise and to evaluate the relationship between NT-proBNP, cardiac function, and exercise tolerance in chronic heart failure. Methods and results A single-centre, cross-sectional pilot study recruited 17 patients with chronic heart failure with reduced left ventricular ejection fraction (age 67 +/- 7 years) and 20 healthy volunteers (age 65 +/- 12 years). The NT-proBNP was measured in the heart failure group. All participants completed maximal graded cardiopulmonary exercise stress testing coupled with gas exchange (using metabolic analyser for determination of exercise tolerance, i.e. peak O-2 consumption) and continuous haemodynamic measurements (i.e. cardiac output and cardiac power output) using non-invasive bioreactance technology. Heart failure patients demonstrated significantly lower peak exercise cardiac function and exercise tolerance than healthy controls, i.e. cardiac power output (5.0 +/- 2.0 vs. 3.2 +/- 1.2 W, P < 0.01), cardiac output (18.2 +/- 6.3 vs. 13.5 +/- 4.0 L/min, P < 0.01), heart rate (148 +/- 23.7 vs. 111 +/- 20.9 beats/min, P < 0.01), and oxygen consumption (24.3 +/- 9.5 vs. 16.8 +/- 3.8 ml/kg/min, P < 0.01). There was no significant relationship between NT-proBNP and cardiac function at rest, i.e. cardiac power output (r = -0.28, P = 0.28), cardiac output (r = -0.18, P = 0.50), and oxygen consumption (r = -0.18, P = 0.50), or peak exercise, i.e. cardiac power output (r = 0.18, P = 0.49), cardiac output (r = 0.13, P = 0.63), and oxygen consumption (r = -0.05, P = 0.84). Conclusions Lack of a significant and strong relationship between the NT-proBNP and measures of cardiac function and exercise tolerance may suggest that natriuretic peptides should be considered with caution in interpretation of the severity of cardiac dysfunction and functional capacity in chronic heart failure.
引用
收藏
页码:449 / 454
页数:6
相关论文